Impact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea - Top-Institutions - MDSpire

Impact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea

  • By

  • Chan Mi Lee

  • Suhyun Kim

  • Hyeon Jae Jo

  • Chang Kyung Kang

  • Wan Beom Park

  • Nam Joong Kim

  • Seungyeon Kim

  • Pyoeng Gyun Choe

  • April 29, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institutes of Health (NIH)
    National Institutes of Health (NIH)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hematology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Infectious Diseases
    • Hematology
    • Immunology

  • #3

    Massachusetts General Hospital (MGH)
    Massachusetts General Hospital (MGH)

    Boston, MA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Rheumatology

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hematology

  • #5

    Seoul National University Hospital
    Seoul National University Hospital

    Seoul, N/A

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Hematology

Original Source(s)

Impact of Rituximab on COVID-19 in Immunocompromised Patients: A Nationwide Cohort Study in Korea

  • by Chan Mi Lee, Suhyun Kim, Hyeon Jae Jo, Chang Kyung Kang, Wan Beom Park, Nam Joong Kim, Seungyeon Kim, Pyoeng Gyun Choe

  • April 29, 2025

Related Content

Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adolescents: results from the cross-sectional observational EAGLE study

Long-term epidemiological patterns of pediatric infectious diseases in an urban district of Shanghai, 2015–2023

MEK1/2 inhibitor ATR-002 reshapes host transcriptome and modulates immune regulatory genes in SARS-CoV-2 infection